New study aims to tame Nintedanib's gut side effects in lung disease
NCT ID NCT06714812
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study observes 100 adults with idiopathic pulmonary fibrosis (IPF) who are taking the drug nintedanib. The goal is to understand who is more likely to get diarrhea as a side effect and to see if lowering the dose helps. Researchers will track diarrhea severity and how dose changes affect patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IPF are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
IRCCS Azienda Ospedaliera-Universitaria di Bologna
Bologna, Bologna, 40138, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a breath test predict lung scarring? new study seeks answers
- New inhaled drug for lung disease tested in healthy people first
- New hope for lung scarring: HSK44459 enters final trial phase
- Healthy volunteers to test experimental lung disease drug
- New drug for lung scarring takes first step in healthy volunteers
- Simple questionnaire could bring palliative care home for lung disease patients